Baseline characteristics of patients included in the U-Act-Early trial.
| TCZ + MTX, n = 106 | TCZ, n = 103 | MTX, n = 108 | |
|---|---|---|---|
| Employed, n (%) | 85 (80) | 79 (77) | 87 (81) |
| Working hours per week, mean (SD) | 24.0 (15.3) | 22.1 (15.5) | 24.6 (15.8) |
| Female, n (%) | 65 (61) | 78 (76) | 69 (64) |
| RF+, n (%) | 75 (71) | 68 (66) | 86 (80) |
| Anti-CCP +, n (%) | 72 (68) | 67 (65) | 84 (78) |
| RF-and/or anti-CCP+, n (%) | 79 (75) | 77 (75) | 93 (86) |
| Age, yrs, median (IQR) | 53.0 (46.0–60.0) | 55.0 (47.0–63.0) | 53.0 (44.5–62.0) |
| Symptom duration, days, median (IQR) | 24.5 (16.0–41.5) | 25.5 (18.0–45.0) | 27.0 (15.0–46.0) |
| DAS28, mean (SD) | 5.2 (1.1) | 5.3 (1.1) | 5.1 (1.2) |
| HAQ, mean (SD) | 1.1 (0.67) | 1.3 (0.66) | 1.1 (0.59) |
| Included in posttrial follow-up, n (%) | 75 (71) | 79 (77) | 72 (67) |
TCZ + MTX: initial TCZ + MTX strategy group; TCZ: initial TCZ + placebo-MTX strategy group; MTX: initial MTX + placebo-TCZ strategy group. Anti-CCP: anticyclic citrullinated peptide antibodies; DAS28: disease activity score in 28 joints (range 0–9.4; higher is more activity); HAQ: Health Assessment Questionnaire (range 0–3; 3 = worst function); MTX: methotrexate; RF: rheumatoid factor; TCZ: tocilizumab.